Your patients trust you with advanced therapies. XELGEN gives you the intelligence layer to show them — in precise biological data — exactly what changed. Move from promising outcomes to proving them.
Every analysis translates 260,000+ biological markers into a report both clinicians and patients understand. Before and after therapy — change made visible.
A single proprietary score — derived from 260,000+ methylation markers — that tells clinicians how ready a patient’s biology is to respond to therapy, and proves to patients exactly what changed.
The BFS™ score emerges from interaction strength across all 15 systems. Gold lines mark the regenerative therapy pathways unique to XELGEN’s training data.
Methylation science is not new. What is new is what our data was trained on.
While other platforms built their models on general aging populations, XELGEN's intelligence was developed exclusively from patients undergoing stem cell therapy, exosome therapy, and regenerative medicine protocols.
When we see a methylation pattern, we know what it means for this therapy, this patient, this stage of treatment.
Your clinic is using XELGEN to give you something that has never been possible before: a precise, plain-language view of how your cells responded to therapy. Not a feeling. Biological evidence.
XELGEN is not just a platform — it’s a global community of leading clinics united by a shared belief: that medicine must measure cellular change, not just symptoms. The BFS™ model improves with every patient analyzed across our global network.
Our partnerships extend from clinics to the exosome biomanufacturers and stem cell specialists who produce the biologics your patients receive — verifying quality at every stage of the regenerative medicine chain.
In a 30-minute demo, we'll walk you through a real Cell Intelligence Report, show you the Clinic Portal, and answer every question your team has.